Background: During antiretroviral therapy (ART), resistant HIV-1 variants may be selected
resulting in clinical failure. Co-infection rate of Hepatitis B virus in AIDS patients in …

Background. It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections
have mild outcomes and a low risk of drug-resistance among patients infected with human …

Background The presence of HBV resistance mutations upon initiation or during
antiretroviral therapy (ART) in HIV-coinfected patients is an important determinant of …

Abstract Hepatitis B virus (HBV)–HIV coinfections are becoming common with information on
HBV genetic diversity and drug resistance still remaining elusive. To evaluate the HBV …

Background In Ethiopia, HBV and HIV are co-circulating. Since patients are not routinely
tested for HBV, the use of antiretroviral drugs could contribute to unintended HBV drug …

Background. The presence of transmitted drug resistance mutations (TDRMs) in
antiretroviral treatment (ART)–naive patients can adversely affect the outcome of ART …

Background In sub-Saharan Africa, the hepatitis B virus (HBV) and human
immunodeficiency virus (HIV) infections are endemic. Although there has been great …

Abstract Study GS-99-907 was a 48-week, phase 3, double-blind, placebo-controlled
intensification trial of tenofovir disoproxil fumarate (tenofovir DF). Antiretroviral-experienced …

ANEJO-OKOPI, Joseph et al. Molecular detection of hepatitis B virus genotype E with
immune escape mutations in chronic hepatitis B patients on long-term antiviral therapy in …

Objectives: To evaluate the maintenance of virological suppression (VS) in antiretroviral-
treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine …